News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kalypsys, Inc. Initiates Second Phase I Clinical Trial of Topical iNOS Inhibitor


4/16/2007 12:07:59 PM

SAN DIEGO--(BUSINESS WIRE)--Kalypsys Inc. announced today it has initiated a second Phase I clinical trial of KD7040, a topical inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The company completed a single dose-escalation study in March of this year and expects to compete a multiple dose-escalation study around mid-2007 (N= approximately 50). Together the studies will evaluate the safety, tolerability and pharmacokinetics of KD7040 versus placebo in healthy volunteers.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES